Q1 2025 Metropolis Healthcare Ltd Earnings Call Transcript
Key Points
- Revenue growth of 13.1% year-over-year, within the guided range of 13% to 15%.
- EBITDA and PAT grew by 21.2% and 31.3%, respectively, indicating strong financial performance.
- Successful expansion into 650 towns, with plans to reach 1,000 towns, showing robust geographical growth.
- Increased focus on specialized tests and bundled wellness and illness packaging, driving higher revenue per patient.
- Strong B2C revenue growth of 18.4%, contributing to 54% of total revenue, up from 51% in the previous year.
- Patient volume growth was partially impacted by a price increase in the B2C segment, causing a temporary dip in volumes.
- Gross margins have only marginally improved despite the increase in B2C mix and focus on Tier 1 cities.
- New lab additions initially result in higher material costs, impacting gross margins.
- Continued provisions for receivables from government contracts, particularly in Delhi, affecting financial stability.
- Competitive intensity remains high, especially in Western India, impacting pricing and market dynamics.
Ladies and gentlemen, good day, and welcome to the Metropolis Healthcare Q1 FY25 Conference Call hosted by Centrum Broking Limited. (Operator Instructions) I now hand the conference over to Mr. Sumit Gupta from Centrum Broking Limited. Thank you, and over to you, sir.
Good morning, and a very warm welcome to all the participants on Metropolis 1Q FY25 Earnings Call hosted by Centrum Broking Limited. With us today, we have the senior management team represented by Ms. Ameera Shah, Chairperson and Executive Director; Mr. Surendran Chemmenkotil, CEO; and Mr. Rakesh Agarwal, CFO.
I will now hand over the call to Ameera ma'am for her opening remarks. Over to you, ma'am.
Thank you, and good morning, everyone. Thanks, everyone, for joining us for this Q1 FY25 earnings call today. I'm joined by Suren and Rakesh and IR our advisers from SGA. We've uploaded our updated results on the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
